Davita Inc vs ZIM Integrated Shipping Services Ltd — how do they compare? Davita Inc trades at $230.44 (market cap $14.92B), while ZIM Integrated Shipping Services Ltd trades at $24.42 (market cap $2.94B). The key difference: Davita Inc is far larger — about 5.1× ZIM Integrated Shipping Services Ltd's market cap, and ZIM Integrated Shipping Services Ltd pays a 20.16% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | ZIM | |
|---|---|---|
Market Cap | $14.92B | $2.94B |
Sector | Health | Industrials |
52-Week High | $235.71 | $29.27 |
52-Week Low | $103.87 | $12.44 |
Enterprise Value | $27.47B | $6.79B |
Dividend Yield | — | 20.16% |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
ZIM Integrated Shipping Services (ZIM) trades at $23.80, down 0.71% on the day, amid bearish technical signals and mixed fundamental performance. The stock faces pressure from regulatory setbacks to its Hapag-Lloyd merger, though recent news highlights rival takeover interest. Financially, 2025 revenue was $6.90B with net income of $479.20M, but 2026 projections show declining profitability. Analyst consensus is split evenly between Hold and Sell, with a price target of $16.75, well below current levels.
The outlook for ZIM is cautious due to merger uncertainty and weakening earnings. Investment opportunities exist if takeover bids materialize, but risks include regulatory hurdles, freight rate volatility, and cash flow pressures. The stock's current price trades at a discount to asset value, yet analyst skepticism and bearish technicals suggest limited near-term upside without positive deal developments.
Trailing returns across standard periods
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →ZIM is a global container liner shipping company that employs a 'global-niche' strategy, focusing on specific trade lanes where it holds a competitive advantage. Unlike larger, asset-heavy competitors, ZIM operates an agile, charter-intensive fleet, allowing it to rapidly adjust capacity to market demand while prioritizing digitalization and specialized cargo like refrigerated (reefer) goods.
Read more on ZIM →